# ACE Inhibitors or ARBs Discontinuation in Context of COVID-19 Pandemic

> **NCT04329195** · PHASE3 · TERMINATED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 44 (actual)

## Conditions studied

- History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection

## Interventions

- **DRUG:** 1: discontinuation of RAS blocker therapy
- **DRUG:** 2: continuation of RAS blocker therapy

## Key facts

- **NCT ID:** NCT04329195
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-09
- **Primary completion:** 2020-12-09
- **Final completion:** 2021-01-09
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** insufficient recrutment
- **Last updated:** 2021-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04329195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04329195, "ACE Inhibitors or ARBs Discontinuation in Context of COVID-19 Pandemic". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04329195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*